Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 136,124 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel sold 136,124 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the sale, the chief executive officer now owns 63,012 shares of the company’s stock, valued at $1,616,257.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock traded up $0.71 during trading on Thursday, hitting $25.91. 869,632 shares of the company were exchanged, compared to its average volume of 429,366. The firm has a market capitalization of $1.84 billion, a P/E ratio of 235.55 and a beta of 0.38. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $14.12 and a 1-year high of $27.88. The firm’s fifty day moving average price is $19.84 and its 200 day moving average price is $19.42.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The company had revenue of $108.30 million during the quarter, compared to analyst estimates of $90.60 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.83% and a negative net margin of 3.10%. The company’s revenue for the quarter was up 51.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.02) EPS. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on KNSA shares. JPMorgan Chase & Co. raised their target price on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Wells Fargo & Company started coverage on Kiniksa Pharmaceuticals in a research report on Friday, May 3rd. They issued an “overweight” rating and a $34.00 price objective for the company. Wedbush lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Evercore ISI lifted their price objective on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $32.00.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently modified their holdings of KNSA. Acadian Asset Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 167.8% during the 1st quarter. Acadian Asset Management LLC now owns 164,568 shares of the company’s stock valued at $3,240,000 after purchasing an additional 103,120 shares in the last quarter. Altitude Crest Partners Inc. bought a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at about $7,999,000. Granahan Investment Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 35.2% during the 4th quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock valued at $12,671,000 after purchasing an additional 188,174 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 8.1% during the 1st quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after purchasing an additional 1,435 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 349.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock valued at $72,000 after purchasing an additional 3,186 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.